LEUTX

Summary

LEUTX (leucine twenty homeobox, HGNC:31953) is a protein-coding gene on chromosome 19q13.2, encoding Paired-like homeodomain transcription factor LEUTX (A8MZ59). Paired-like homeobox transcription factor involved in embryogenesis.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in chromatin. Predicted to be active in nucleus.

Source: NCBI Gene 342900 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 25 total
• MANE Select transcript: NM_001382345

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31953
Approved symbol	LEUTX
Name	leucine twenty homeobox
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000213921
Ensembl biotype	protein_coding
OMIM	618701
Entrez	342900

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000396841, ENST00000638280

RefSeq mRNA: 2 — MANE Select: NM_001382345 NM_001143832, NM_001382345

CCDS: CCDS92615

Canonical transcript exons

ENST00000638280 — 3 exons

Exon	Start	End
ENSE00003803257	39785698	39786291
ENSE00003806262	39778854	39778927
ENSE00003810096	39784527	39784678

Expression profiles

Bgee: expression breadth tissue_specific, 9 present calls, max score 97.16.

Top tissues by expression

125 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	97.16	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	52.61	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
sural nerve	UBERON:0015488	30.93	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
smooth muscle tissue	UBERON:0001135	29.47	silver quality
prefrontal cortex	UBERON:0000451	29.04	gold quality
placenta	UBERON:0001987	28.66	silver quality
monocyte	CL:0000576	28.39	silver quality
leukocyte	CL:0000738	28.32	silver quality
duodenum	UBERON:0002114	28.14	gold quality
liver	UBERON:0002107	28.04	gold quality
lymph node	UBERON:0000029	27.57	gold quality
tonsil	UBERON:0002372	27.05	gold quality
islet of Langerhans	UBERON:0000006	27.00	gold quality
vermiform appendix	UBERON:0001154	26.42	gold quality
gall bladder	UBERON:0002110	25.98	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	25.89	gold quality
urinary bladder	UBERON:0001255	25.72	gold quality
muscle of leg	UBERON:0001383	24.98	gold quality
primary visual cortex	UBERON:0002436	24.61	gold quality
pancreas	UBERON:0001264	24.17	gold quality
rectum	UBERON:0001052	24.16	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2597.1	LEUTX	Paired-related HD

JASPAR matrix evidence (PMIDs): PMID:27578796

Literature-anchored findings (GeneRIF, showing 2)

• Rapid Evolution of the Embryonically Expressed Homeobox Gene LEUTX within Primates. (PMID:37232378)
• Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion. (PMID:38500181)

Cross-species orthologs

0 orthologs

Paralogs (3): DBX1 (ENSG00000109851), HLX (ENSG00000136630), DBX2 (ENSG00000185610)

Protein

Protein identifiers

Paired-like homeodomain transcription factor LEUTX — A8MZ59 (reviewed: A8MZ59)

Alternative names: Leucine-twenty homeobox, Paired-like homeobox transcription factor LEUTX

All UniProt accessions (1): A8MZ59

UniProt curated annotations — full annotation on UniProt →

Function. Paired-like homeobox transcription factor involved in embryogenesis. May act as a regulator of embryo genome activation. Binds to a 36 bp DNA elements containing a 5’-TAATCC-3’ sequence motif, referred to as EEA motif (EGA-enriched Alu-motif), present in the promoters of target genes activated in early embryos. Inactive transcriptional activity.

Subcellular location. Nucleus.

Domain organisation. The homeobox contain essential residues (Ile-54, Lys-57, Ala-61) for binding to the 5’-TAATCC-3’ motif of the targe gene promoters. The homeobox is incomplete and cannot bind to the 36 bp motif found in the promoters of the target genes. The 9aaTAD motif is a conserved putative nine amino acid transactivation motifs in C-terminus of the LEUTX region.

Similarity. Belongs to the paired homeobox family.

Isoforms (2)

UniProt ID	Names	Canonical?
A8MZ59-2	1, LEUTX.n	yes
A8MZ59-1	2, LEUTX.R

RefSeq proteins (2): NP_001137304, NP_001369274* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR017970	Homeobox_CS	Conserved_site

Pfam: PF00046

UniProt features (17 total): short sequence motif 4, site 3, mutagenesis site 2, sequence conflict 2, region of interest 2, chain 1, DNA-binding region 1, splice variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A8MZ59-F1	68.84	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 57 (required for binding to the 5’-taatcc-3’ sequence); 61 (required for binding to the 5’-taatcc-3’ sequence); 54 (required for binding to the 5’-taatcc-3’ sequence)

Mutagenesis-validated functional residues (2):

Position	Phenotype
54	increased transcriptional activity; when associated with ala-61-val, restores wild-type transcriptional activity.
61	abolished catalytic activity; when associated with ile-54-thr, restores wild-type transcriptional activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9819196	Zygotic genome activation (ZGA)
R-HSA-1266738	Developmental Biology
R-HSA-9816359	Maternal to zygotic transition (MZT)

MSigDB gene sets: 14 (showing top): KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, WP_PREIMPLANTATION_EMBRYO, GOMF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, GOMF_CIS_REGULATORY_REGION_SEQUENCE_SPECIFIC_DNA_BINDING, REACTOME_MATERNAL_TO_ZYGOTIC_TRANSITION_MZT, REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA, PULVER_FOREY_PERTURB_ATTRITION_S, GOMF_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATORY_REGION_SEQUENCE_SPECIFIC_DNA_BINDING, chr19q13, GOCC_CHROMATIN, FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_UP, FLORIO_HUMAN_NEOCORTEX

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Maternal to zygotic transition (MZT)	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1

Protein interactions and networks

STRING

512 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LEUTX	DPRX	A6NFQ7	803
LEUTX	KHDC1L	Q5JSQ8	795
LEUTX	DUX4L2	P0CJ85	732
LEUTX	TPRX1	Q8N7U7	729
LEUTX	DUXB	A0A1W2PPF3	727
LEUTX	DUXA	A6NLW8	721
LEUTX	TRIM43	Q96BQ3	718
LEUTX	ZSCAN4	Q8NAM6	667
LEUTX	MBD3L2	Q8NHZ7	663
LEUTX	PRAMEF2	O60811	653
LEUTX	KHDC1	Q4VXA5	627
LEUTX	PRAMEF1	O95521	623
LEUTX	NANOGNB	Q7Z5D8	581
LEUTX	MBD3L3	A6NE82	580
LEUTX	ANHX	E9PGG2	531

IntAct

139 interactions, top by confidence:

A	B	Type	Score
OLFM4	LEUTX	psi-mi:“MI:0915”(physical association)	0.560
NAPB	LEUTX	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	ZNF646	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	STATH	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	CNIH1	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	SLC41A2	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	EMP3	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TMEM60	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	CMTM3	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TMEM147	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	VAMP4	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	CMTM5	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TMEM128	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	FAM24B	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	GOSR2	psi-mi:“MI:0915”(physical association)	0.560
	LEUTX	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	SLC30A8	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	AQP3	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TMEM187	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	MS4A1	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TTPA	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	AGPAT4	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	CXCL9	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	NDRG4	psi-mi:“MI:0915”(physical association)	0.560
PRB1	LEUTX	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	TTMP	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	UNC93B1	psi-mi:“MI:0915”(physical association)	0.560
LEUTX	AQP2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (46): LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid), LEUTX (Two-hybrid)

ESM2 similar proteins: A0A1W2PQ72, A7J1T0, A7J1T2, A7MBB4, A8MZ59, D3ZXW3, M0R5D6, O36371, O43283, O43310, O73622, O95073, P03177, P10242, P21705, P46200, Q0P4H6, Q1HKZ5, Q1HVD1, Q1LVK9, Q22811, Q2NKQ1, Q3KSQ2, Q3UPF5, Q535K8, Q562B4, Q567C6, Q5R8X7, Q5ZI27, Q6DGX3, Q6INH1, Q6J1H4, Q6PEE2, Q6ZTZ1, Q71M44, Q7SXL7, Q80T85, Q8BFX3, Q8BIL2, Q8BKE5

Diamond homologs: A1YEY5, A1YFI3, A1YG57, A2T733, A2T7P4, A6NJG6, A6NJT0, A6NNA5, A6YP92, A8MZ59, F1NEA7, G5EC89, O08934, O14813, O15266, O35085, O35137, O35160, O35690, O35750, O42115, O43186, O54751, O60902, O70137, O73592, O73917, O75364, O77215, O93385, O95076, P0DMV5, P22810, P26367, P26630, P29454, P29506, P32242, P32243, P47237

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

257 predictions. Top by Δscore:

Variant	Effect	Δscore
19:39776673:AAGG:A	donor_loss	1.0000
19:39785694:TTA:T	acceptor_loss	1.0000
19:39785695:TA:T	acceptor_loss	1.0000
19:39785696:A:AG	acceptor_gain	1.0000
19:39785696:A:AT	acceptor_loss	1.0000
19:39785697:G:A	acceptor_loss	1.0000
19:39785697:G:GT	acceptor_gain	1.0000
19:39785697:GAT:G	acceptor_gain	1.0000
19:39785697:GATC:G	acceptor_gain	1.0000
19:39785697:GATCT:G	acceptor_gain	1.0000
19:39784525:AGAAG:A	acceptor_gain	0.9900
19:39784526:GAAGG:G	acceptor_gain	0.9900
19:39784652:C:G	donor_gain	0.9900
19:39784671:T:TA	donor_gain	0.9900
19:39784672:A:AA	donor_gain	0.9900
19:39785697:GA:G	acceptor_gain	0.9900
19:39776676:G:GG	donor_gain	0.9800
19:39785694:TTAGA:T	acceptor_gain	0.9800
19:39785695:TAGAT:T	acceptor_gain	0.9800
19:39785696:AGATC:A	acceptor_gain	0.9800
19:39784524:CAGA:C	acceptor_gain	0.9700
19:39784525:A:AG	acceptor_gain	0.9700
19:39784525:AGAA:A	acceptor_gain	0.9700
19:39784526:G:GG	acceptor_gain	0.9700
19:39784526:GA:G	acceptor_gain	0.9700
19:39784526:GAAG:G	acceptor_gain	0.9700
19:39776674:AG:A	donor_gain	0.9600
19:39776675:GG:G	donor_gain	0.9600
19:39784676:AAG:A	donor_gain	0.9600
19:39785693:CTTAG:C	acceptor_gain	0.9600

AlphaMissense

1279 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:39785704:T:C	F56L	0.991
19:39785706:C:A	F56L	0.991
19:39785706:C:G	F56L	0.991
19:39785705:T:C	F56S	0.983
19:39785709:G:C	K57N	0.981
19:39785709:G:T	K57N	0.981
19:39785717:G:C	R60P	0.978
19:39785710:A:G	N58D	0.973
19:39784562:T:C	F15L	0.972
19:39784564:T:A	F15L	0.972
19:39784564:T:G	F15L	0.972
19:39785711:A:G	N58S	0.970
19:39784587:T:C	L23S	0.965
19:39784644:C:A	A42D	0.965
19:39785711:A:C	N58T	0.953
19:39785716:C:A	R60S	0.952
19:39784616:C:T	P33S	0.951
19:39784563:T:C	F15S	0.948
19:39785701:T:A	W55R	0.946
19:39785701:T:C	W55R	0.946
19:39785714:A:C	Q59P	0.946
19:39784563:T:G	F15C	0.943
19:39785712:C:A	N58K	0.941
19:39785712:C:G	N58K	0.941
19:39785703:G:C	W55C	0.940
19:39785703:G:T	W55C	0.940
19:39785719:G:C	A61P	0.940
19:39785707:A:G	K57E	0.934
19:39785711:A:T	N58I	0.932
19:39785705:T:G	F56C	0.931

dbSNP variants (sampled 300 via entrez): RS1000568731 (19:39780811 C>T), RS1000694517 (19:39785911 G>A), RS1000704423 (19:39786212 A>G), RS1000831814 (19:39780734 T>C), RS1000914101 (19:39774716 G>A), RS1000968527 (19:39780485 T>G), RS1000969525 (19:39780529 A>C), RS1001448779 (19:39776384 T>C,G), RS1001512367 (19:39774852 A>G), RS1001708620 (19:39781624 C>T), RS1001850615 (19:39774985 T>C,G), RS1002019673 (19:39786619 C>T), RS1002085807 (19:39781015 C>T), RS1002258477 (19:39786522 G>A), RS1002459984 (19:39786720 G>A)

Disease associations

OMIM: gene MIM:618701 | disease phenotypes: MIM:125853, MIM:240900

GenCC curated gene-disease

Mondo (2): type 2 diabetes mellitus (MONDO:0005148), hypoinsulinemic hypoglycemia and body hemihypertrophy (MONDO:0009416)

Orphanet (1): Hypoinsulinemic hypoglycemia and body hemihypertrophy (Orphanet:293964)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006976_36	Macular thickness	5.000000e-17

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003924	Diabetes Mellitus, Type 2	C18.452.394.750.149; C19.246.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00006163	PHASE4	COMPLETED	Computer-assisted Diabetes Self-management Interventions
NCT00036504	PHASE4	COMPLETED	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
NCT00044460	PHASE4	COMPLETED	Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00110370	PHASE4	COMPLETED	Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00118950	PHASE4	COMPLETED	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963	PHASE4	COMPLETED	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00121966	PHASE4	COMPLETED	South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT00123604	PHASE4	COMPLETED	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123643	PHASE4	COMPLETED	Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
NCT00124397	PHASE4	COMPLETED	Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00129233	PHASE4	COMPLETED	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00133718	PHASE4	COMPLETED	A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
NCT00135070	PHASE4	TERMINATED	Hospital In-Patient Insulin Study
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00144144	PHASE4	UNKNOWN	A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00149331	PHASE4	COMPLETED	The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00174681	PHASE4	COMPLETED	Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174824	PHASE4	COMPLETED	Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00177398	PHASE4	COMPLETED	Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00179400	PHASE4	COMPLETED	The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00191178	PHASE4	COMPLETED	Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191464	PHASE4	COMPLETED	Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00192803	PHASE4	UNKNOWN	Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00202033	PHASE4	COMPLETED	Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00205660	PHASE4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00212290	PHASE4	COMPLETED	Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212303	PHASE4	COMPLETED	Exercise Training in Type 2 Diabetes and Hypertension
NCT00225342	PHASE4	WITHDRAWN	Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00238472	PHASE4	COMPLETED	A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00239538	PHASE4	COMPLETED	SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00240253	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
NCT00240422	PHASE4	COMPLETED	Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
NCT00241085	PHASE4	COMPLETED	Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus